Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEMO trial: binimetinib versus dacarbazine in NRAS mutation-positive metastatic melanoma
2012-003593-51Phase 3Completed
- Sponsor
- Array BioPharma
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of binimetinib in melanoma (2 arms), sponsored by Array BioPharma. Primary endpoint: Progression-free survival. Started Feb 2013; status: completed.
02
Drugs
binimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2012-003593-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003593-51.